Dexmedetomidine alleviated sepsisinduced myocardial ferroptosis and septic heart injury
Food and Drug Administration (FDA) to improve glycemic control in patients with type 2 diabetes and reduce the risk of myocardial infarction, stroke or cardiovascular death in patients with both type 2 diabetes and cardiovascular disease
Oral administration of myricetin significantly reduces Fe 2+ levels in the substantia nigra of PD rats, inhibits neuronal ferroptosis, decreases ROS production, downregulates malondialdehyde (MDA) and -synuclein (-Syn) expression, elevates GSH levels, and ameliorates motor deficits
This dual approach discouraging harmful choices while promoting affordable, nutritious alternatives has the potential to reshape Americas food landscape and improve public health for generations to come
Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK
Fernandez-Hernando and Suarez, 2020)